# National Heart, Lung, and Blood Institute (NHLBI): Phase 1 study closed enrollment, 40 enrolled (Pulmonary Arterial Hypertension PAH)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| Study | Study of Intravenous ZMA001 in Healthy Subjects |
| NCT ID | NCT05967299 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Pulmonary Arterial Hypertension PAH |
| Intervention types | other, drug |
| Target enrollment | 40 |
| Site countries | United States |
| Posted | 2023-08-01 |
| Planned start | 2023-11-27 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05967299). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.